Please ensure Javascript is enabled for purposes of website accessibility

Acadia Pharmaceuticals Delivers Record Q3 Revenue, Fueled by Antipsychotic Drug Nuplazid

By Keith Speights - Oct 31, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech continues to enjoy great momentum for its only approved drug, with a big new FDA approval potentially on the way.

Acadia Pharmaceuticals (ACAD -2.54%) has been a huge winner so far in 2019. The biotech's Parkinson's disease psychosis (PDP) medicine Nuplazid (pimavanserin) has picked up significant sales momentum, and it's reported some positive clinical results.

The company announced its third-quarter results after the market closed on Wednesday. And Acadia had even more good news. Here are the highlights from the drugmaker's Q3 update.

Gloved hand on a beaker with a $100 bill in it and $100 bills under it

Image source: Getty Images.

By the numbers

Acadia reported that its revenue jumped 62% year over year in the third quarter to an all-time high of $94.6 million. This figure easily topped the Wall Street consensus revenue estimate of $88.5 million.

The company announced a net loss of $42 million, or $0.29 per share, based on generally accepted accounting principles (GAAP). This reflected an improvement from the GAAP net loss of $62.1 million, or $0.50 per share, recorded in the same period in 2018. It also came in better than the average analysts' net loss estimate of $0.40 per share.

Acadia ended the third quarter with cash, cash equivalents, and short-term investments of $683.8 million. This represented an increase from the $473.5 million on hand as of Dec. 31, 2018.

Behind the numbers

Sales for Acadia's one approved drug, Nuplazid, continued to soar in the third quarter, generating all of the company's revenue. Acadia enjoyed a boost from a favorable Medicare accrual adjustment, which added $2.2 million to its Q3 net sales.

Thanks to the sizzling momentum for Nuplazid, Acadia's bottom line trended in the right direction despite another quarterly loss. The company's operating expenses increased as well. However, Acadia was able to keep its spending growth rate to around 17%, well below its revenue growth rate. 

The drugmaker's significantly better cash position at the end of the third quarter stemmed mainly from a public stock offering completed in September that generated net proceeds of $271.5 million. Acadia also benefited from employee option exercises totaling $55.1 million.

In addition to its solid financial performance in Q3, Acadia has several key developments on other fronts, including:

  • Achieved the primary endpoint in Harmony phase 3 clinical study evaluating pimavanserin in dementia-related psychosis.
  • Presented positive initial data from a phase 2 study evaluating pimavanserin as a monotherapy or as an adjunct therapy with selective serotonin reuptake inhibitor(SSRI) and serotonin and norepinephrine reuptake inhibitor (SNRI) in treating depressive symptoms.
  • Kicked off the late-stage Lavendar clinical study evaluating trofinetide in treating Rett syndrome.

Looking ahead

After its strong performance in Q3, Acadia now anticipates full-year 2019 revenue will be between $330 million and $340 million. That's up from the company's previous guidance of full-year revenue between $320 million and $330 million.

Perhaps the most important thing for investors to watch is Acadia's progress in winning U.S. Food and Drug Administration (FDA) approval for Nuplazid in treating dementia-related psychosis (DRP) after the stellar Harmony late-stage study results. Acadia CEO Steve Davis believes that Nuplazid "has the potential to be one of the first new treatments approved for people with dementia in over 15 years and the first-ever FDA-approved treatment for DRP."

However, biotech stocks tend to price in much of the potential for highly anticipated FDA approvals. That's the case with Acadia right now. This stock could move higher, though, and is one for investors to keep their eyes on.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
$15.74 (-2.54%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.